Try our beta test site
56 studies found for:    Open Studies | Lymphoma OR CLL | Chimeric antigen receptor OR Engineered Lymphocyte Therapy
Show Display Options
Rank Status Study
1 Not yet recruiting Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
Condition: Lymphoma
Intervention: Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
2 Recruiting A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Chimeric Antigen Receptor Modified T cells Targeting CD19
3 Not yet recruiting Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
Condition: Lymphoma, B Cell
Interventions: Biological: IL-2 pre-treated CD19 cells;   Biological: IL-7/IL-15 pre-treated CD19 cells
4 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Condition: LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Intervention: Biological: CART 19
5 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   Non-hodgkin Lymphoma,B Cell;   Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
6 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
7 Recruiting CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Conditions: Acute Myeloid Leukemia;   Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;   T-cell Prolymphocytic Leukemia;   T-cell Large Granular Lymphocytic Leukemia;   Peripheral T-cell Lymphoma, NOS;   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma, Nasal Type;   Enteropathy-type Intestinal T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma
Intervention: Biological: anti-CD7 CAR-pNK cells
8 Recruiting CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Biological: CART30
9 Recruiting PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: anti-CD19 CAR-NK cells
10 Recruiting Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Conditions: CD19+ Diffuse Large B-cell Lymphomas;   Follicular Lymphomas;   Mantle Cell Lymphomas
Intervention: Drug: Pembrolizumab
11 Not yet recruiting CD19-redirected Autologous Cells (CAR-CD19 T Cells)
Condition: CD19 Positive Malignant B-cell Leukemia and Lymphoma
Interventions: Genetic: CAR-CD19 T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
12 Recruiting CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: PCAR-019 (anti-CD19 CAR-T cells)
13 Recruiting Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: PCAR-019 (anti-CD19 CAR-T cells)
14 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
15 Recruiting T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
Interventions: Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
16 Recruiting Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Conditions: Recurrent B-Cell Tumor;   Refractory B-Cell Tumor
Intervention: Biological: CD19-specific chimeric antigen receptor
17 Recruiting Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
Conditions: Leukemia, B-Cell;   Lymphoma, B-Cell
Intervention: Biological: CD19CART
18 Recruiting A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects
Condition: Refractory Diffuse Large B-Cell Lymphoma
Intervention: Biological: C-CAR-011
19 Recruiting Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Conditions: Non-Hodgkin's Lymphoma;   B-Cell ALL;   B-Cell CLL
Interventions: Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2;   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1
20 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Lymphoma
Intervention: Combination Product: Drugs and Anti-CD19-CAR transduced T cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.